AYTU BIOPHARMA, INC: 10-Q filed 2015-04-15

Name: AYTU BIOPHARMA, INC: 10-Q filed 2015-04-15
Creator: AYTU BIOPHARMA, INC

What AYTU BIOPHARMA, INC reported in its quarterly report filed 2015-04-15 (fiscal Q2 2015): 18 published measures, 47 facts as tagged in accession 0001079974-15-000272.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-04-15
Fiscal period: fiscal Q2 2015
Accession: 0001079974-15-000272 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-02-28	7,985	USD
At 2014-08-31	5,513	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2015-02-28	-52,918	USD
At 2014-08-31	-44,989	USD
At 2013-08-31	-110,856	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-12-01 to 2015-02-28	-9,875	USD	90
2014-09-01 to 2015-02-28	-25,629	USD	181
2013-09-01 to 2014-08-31	-61,723	USD	365
2013-12-01 to 2014-02-28	-22,196	USD	90
2013-09-01 to 2014-02-28	-38,703	USD	181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-09-01 to 2015-02-28	-22,723	USD	181
2013-09-01 to 2014-02-28	-15,194	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2014-09-01 to 2015-02-28	20,508	USD	181
2013-09-01 to 2014-02-28	13,516	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-02-28	-656,056	USD
At 2014-08-31	-630,427	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-02-28	375	USD
At 2014-08-31	2,739	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-12-01 to 2015-02-28	-9,401	USD	90
2014-09-01 to 2015-02-28	-24,692	USD	181
2013-12-01 to 2014-02-28	-20,559	USD	90
2013-09-01 to 2014-02-28	-35,566	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-02-28	7,129	USD
At 2014-08-31	2,486	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-12-01 to 2015-02-28	474	USD	90
2014-09-01 to 2015-02-28	937	USD	181
2013-12-01 to 2014-02-28	1,637	USD	90
2013-09-01 to 2014-02-28	3,137	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-02-28	60,903	USD
At 2014-08-31	50,502	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-02-28	4,266	USD
At 2014-08-31	310	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-02-28	5,835,402	shares
At 2014-08-31	5,735,402	shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-02-28	1,600	USD
At 2014-08-31	1,600	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-12-01 to 2015-02-28	4,987	USD	90
2014-09-01 to 2015-02-28	10,261	USD	181
2013-12-01 to 2014-02-28	4,873	USD	90
2013-09-01 to 2014-02-28	11,494	USD	181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-09-01 to 2015-02-28	2,364	USD	181
2013-09-01 to 2014-02-28	2,390	USD	181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-12-01 to 2015-02-28	-474	USD	90
2014-09-01 to 2015-02-28	-937	USD	181
2013-12-01 to 2014-02-28	-1,637	USD	90
2013-09-01 to 2014-02-28	-3,137	USD	181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-09-01 to 2015-02-28	15,000	USD	181

Inspect the source

Entity: AYTU BIOPHARMA, INC / CIK 0001385818
Captured: 2026-09-20T07:58:53.461Z
SEC response SHA-256: 3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))